Wall Street Zen Downgrades Establishment Labs (NASDAQ:ESTA) to Sell

Establishment Labs (NASDAQ:ESTA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Several other brokerages also recently issued reports on ESTA. Needham & Company LLC reissued a "buy" rating and set a $48.00 price target on shares of Establishment Labs in a report on Friday, June 13th. Citigroup boosted their price target on shares of Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a report on Wednesday. Finally, BTIG Research initiated coverage on shares of Establishment Labs in a report on Friday, May 16th. They set a "buy" rating and a $62.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Establishment Labs currently has an average rating of "Moderate Buy" and an average price target of $51.80.

Establishment Labs Stock Down 2.3%

ESTA stock opened at $44.89 on Friday. The company has a debt-to-equity ratio of 5.72, a current ratio of 3.36 and a quick ratio of 2.05. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $52.41. The firm has a fifty day moving average price of $38.21 and a two-hundred day moving average price of $36.97. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -14.48 and a beta of 0.80.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The firm had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. During the same quarter in the previous year, the firm earned ($0.58) earnings per share. The firm's revenue for the quarter was up 11.3% compared to the same quarter last year. Research analysts predict that Establishment Labs will post -2.41 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

Institutional investors have recently bought and sold shares of the stock. Elevation Point Wealth Partners LLC acquired a new stake in Establishment Labs in the first quarter worth about $207,000. Raymond James Financial Inc. acquired a new stake in Establishment Labs in the fourth quarter worth about $5,494,000. Northern Trust Corp lifted its holdings in Establishment Labs by 53.9% in the fourth quarter. Northern Trust Corp now owns 28,165 shares of the company's stock worth $1,298,000 after purchasing an additional 9,865 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Establishment Labs in the 4th quarter valued at about $161,000. Finally, Swiss National Bank lifted its holdings in Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock valued at $1,774,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.